Full Press Release Details
ClearPoint Neuro, Inc. Reports Record Revenue in Preliminary
Fourth Quarter 2020 Results
IRVINE, CA, January 12, 2021 - ClearPoint
Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery
to the brain, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020.
Preliminary 2020 Results:
"We were pleased with our revenue performance in the fourth quarter,
augmented by capital purchases of ClearPoint installations," commented Joe Burnett, President and Chief Executive Officer
of ClearPoint Neuro. "While some hospitals have resumed capital acquisition activities, we, like most of our peers, continue
to see the adverse impact of the most recent surge of COVID-19 cases globally, and we expect downward pressure on elective procedures
to continue at least through the first half of 2021. I look forward to providing more detail on our full fourth quarter earnings
call, the specifics of which we plan to announce next month."
About ClearPoint Neuro
ClearPoint Neuro's mission is to improve and restore quality of life
to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications
of the Company's current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and
delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is
CE-marked, and is installed in 60 active clinical sites in the United States. The Company's SmartFlow cannula is being
used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research
to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company's field-based
clinical specialist team which offers support and services for our partners. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements herein concerning the Company's plans, growth and strategies
may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future
events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating
to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's
actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties
and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from
sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize
and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; and estimates regarding
the sufficiency of the Company's cash resources. More detailed information on these and additional factors that could affect
the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report
on Form 10-K for the year ended December 31, 2019, and the Company's Quarterly Report on Form 10-Q for the three months ended
September 30, 2020, both of which have been filed with the Securities and Exchange Commission, and the Company's Annual Report
on Form 10-K for the year ended December 31, 2020, which the Company intends to file with the Securities and Exchange Commission
on or before March 31, 2021.
Danilo D'Alessandro, Chief Financial Officer
Jacqueline Keller, Vice President, Marketing